These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17210887)

  • 1. Enzyme replacement for infantile Pompe disease: the first step toward a cure.
    Wagner KR
    Neurology; 2007 Jan; 68(2):88-9. PubMed ID: 17210887
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzyme replacement in Pompe disease with an alpha-glucosidase-low density lipoprotein complex.
    Williams JC; Murray AK
    Birth Defects Orig Artic Ser; 1980; 16(1):415-23. PubMed ID: 7004520
    [No Abstract]   [Full Text] [Related]  

  • 3. First treatment for Pompe disease.
    FDA Consum; 2006; 40(4):3. PubMed ID: 17245826
    [No Abstract]   [Full Text] [Related]  

  • 4. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
    van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
    Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
    Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
    Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
    Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
    Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
    Katzin LW; Amato AA
    J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
    Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pompe disease therapy presents coverage challenge.
    Morrow T
    Manag Care; 2006 Jun; 15(6):63-4. PubMed ID: 16838889
    [No Abstract]   [Full Text] [Related]  

  • 11. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
    Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
    Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pompe disease in infants and children.
    Kishnani PS; Howell RR
    J Pediatr; 2004 May; 144(5 Suppl):S35-43. PubMed ID: 15126982
    [No Abstract]   [Full Text] [Related]  

  • 13. alpha-glucosidase (CHO) (Genzyme).
    Lachmann RH
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1101-10. PubMed ID: 15535432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease.
    van Capelle CI; Winkel LP; Hagemans ML; Shapira SK; Arts WF; van Doorn PA; Hop WC; Reuser AJ; van der Ploeg AT
    Neuromuscul Disord; 2008 Jun; 18(6):447-52. PubMed ID: 18508267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series.
    Wang LY; Ross AK; Li JS; Dearmey SM; Mackey JF; Worden M; Corzo D; Morgan C; Kishnani PS
    Paediatr Anaesth; 2007 Aug; 17(8):738-48. PubMed ID: 17596219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
    Hunley TE; Corzo D; Dudek M; Kishnani P; Amalfitano A; Chen YT; Richards SM; Phillips JA; Fogo AB; Tiller GE
    Pediatrics; 2004 Oct; 114(4):e532-5. PubMed ID: 15466083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L; Straub V; Neudorf U; Voit T
    Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.
    Ebbink BJ; Aarsen FK; van Gelder CM; van den Hout JM; Weisglas-Kuperus N; Jaeken J; Lequin MH; Arts WF; van der Ploeg AT
    Neurology; 2012 May; 78(19):1512-8. PubMed ID: 22539577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
    Illés Z; Várdi Visy K
    Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early pathologic changes and responses to treatment in patients with later-onset Pompe disease.
    Chien YH; Lee NC; Huang PH; Lee WT; Thurberg BL; Hwu WL
    Pediatr Neurol; 2012 Mar; 46(3):168-71. PubMed ID: 22353292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.